Table 4.
Results of univariate and multivariate analyses of factors affecting post-progression survival (n = 38).
| Variables | Category | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P-value | HR | 95% CI | P-value | ||
| Age (years) | ≥65 vs. <65 | 1.03 | 0.33–3.18 | 0.97 | – | – | – |
| Sex | Female vs. Male | 0.97 | 0.36–2.65 | 0.96 | – | – | – |
| ECOG PS | ≥2 vs. 0–1 | 4.78 | 1.60–14.32 | 0.005 | 1.46 | 0.29–7.18 | 0.65 |
| Brain metastasis | Yes vs. No | 0.95 | 0.33–2.75 | 0.93 | – | – | – |
| Liver metastasis | Yes vs. No | 2.15 | 0.76–6.05 | 0.15 | – | – | – |
| Bone metastasis | Yes vs. No | 1.54 | 0.59–4.02 | 0.38 | – | – | – |
| NLR | High vs. Low | 5.82 | 1.76–19.24 | 0.004 | 4.12 | 0.86–19.76 | 0.08 |
| PLR | High vs. Low | 0.87 | 0.31–2.49 | 0.80 | – | – | – |
| Total BTS | Large vs. Small | 4.32 | 1.29–14.45 | 0.02 | 3.03 | 0.67–13.75 | 0.15 |
BTS, baseline tumor size; CI, confidential interval; ECOG PS, Eastern Cooperative Oncology Group performance status; ES, extensive-stage; HR, hazard ratio; LS, limited-stage; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio.